Drugs / ET0038
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05525559 | Nov 2022 → Nov 2024 | neoplasm | Etern BioPharma (Shanghai) Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT05354843 | Oct 2021 → Oct 2023 | neoplasm | Etern BioPharma (Shanghai) Co., Ltd | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-03-09 | Antengene Corporation | Results Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting antengene.com ↗
These data provide several promising combination strategies for ATG-012 that could be utilized in clinical testing for cancer patients with the KRAS G12C mutation. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-03-09 | Antengene Corporation | Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting antengene.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ET0038 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05525559 ↗ |
| Action | Inhibit | “SHP2 Inhibitor ET0038” NCT05525559 ↗ |
| Route | Oral | “ET0038 will be administered orally once daily” NCT05354843 ↗ |